<html>
<head>
<title>Form 8-K
</title>
</head>
<body>




<hr size=3 noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>UNITED STATES<br>
SECURITIES AND EXCHANGE COMMISSION<br></b></font>
<font face="Times New Roman, Times, Serif" size=2>Washington, DC 20549</font>
</p>

<hr width=25% noshade>

<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>FORM 8-K<br>
<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>CURRENT REPORT</b></font><br><font face="Times New Roman, Times, Serif" size=2><b>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934<br></b></font></p>
<p align=center>
<font face="Times New Roman, Times, Serif" size=2>Date of Report&nbsp;&nbsp;(Date of earliest event reported):&nbsp;&nbsp;&nbsp;&nbsp;October 20, 2005</font><br></p>
<hr width=25% noshade>
<p align=center>
<font face="Times New Roman, Times, Serif" size=5><b>MILLENNIUM PHARMACEUTICALS, INC.</b></font><br><font face="Times New Roman, Times, Serif" size=2>(Exact name of registrant as specified in its charter)</font></p>
<table width=100% border=0 cellpadding=0 cellspacing=0 align=center>

<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>Delaware</b></font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>0-28494</b></font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2><b>04-3177038</b></font></td>
</tr>
<tr>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(State or other jurisdiction<br>of incorporation)</font></td>
<td width=34% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(Commission file number)</font></td>
<td width=33% align=center valign=top><font face="Times New Roman, Times, Serif" size=2>(IRS&nbsp;Employer<br>Identification&nbsp;No.)</font></td>
</tr>




</table>


<p align=center><font face="Times New Roman, Times, Serif" size=2><b>40 Landsdowne Street<br>Cambridge, Massachusetts 02139</b><br>
(Address of principal executive offices)&nbsp;(zip code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>(617)&nbsp;&nbsp;679-7000<br></b>
(Registrant's telephone number, including area code)</font></p>

<p align=center><font face="Times New Roman, Times, Serif" size=2><b>Not applicable<br></b>
(Former name or former address if changed since last report)</font></p>

<p align=left><font face="Times New Roman, Times, Serif" size=2>Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></p>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top width=2%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=94%><font face="Times New Roman, Times, Serif" size=2>Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></td></tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#144;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</font></td></tr>


</table>




<hr size=3 noshade width=100%>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=top>

<td width=9%><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;1.01</b></font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2><b>Entry into a Material Definitive Agreement.</b></font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
</table>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On October 20, 2005, the Company and
Linda Pine, senior vice president, human resources, agreed that Ms. Pine would be
transitioning to a senior advisory role as a non-executive part-time employee. This change
is expected to take place in the first quarter of 2006 and last through January 2007, at
which point Ms. Pine plans to retire. Ms. Pine will continue to be paid her full time
salary through her retirement date and will also be eligible for a bonus payout under the
Company&#146;s 2005 Success Sharing Bonus Plan. In connection with Ms. Pine&#146;s change
in employment capacity, she and the Company have agreed that as of January 1, 2006, she
will no longer be eligible for new stock option grants from the Company or for
participation in the Company&#146;s 2006 Success Sharing Bonus Plan. Ms. Pine will
continue to vest into her existing stock options through her retirement date and upon her
retirement, Ms. Pine&#146;s vested options will remain exercisable as provided in the
plans under which they were issued. </FONT></P>


<table border=0 cellpadding=0 cellspacing=0>
<tr valign=top>

<td width=9%><font face="Times New Roman, Times, Serif" size=2><b>Item&nbsp;&nbsp;&nbsp;2.02</b></font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2><b>Results of Operations and Financial Condition.</b></font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
</table>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>On October 26, 2005, Millennium
Pharmaceuticals, Inc. (the &#147;Company&#148;) issued a press release to report the
Company&#146;s financial results for the quarter ended September 30, 2005. The full text
of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The information in Item 2.02 and
Exhibit 99.1 of this Form 8-K shall not be deemed &#147;filed&#148; for purposes of
Section 18 of the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;) or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company&#146;s financial
position prepared in accordance with generally accepted accounting principles (GAAP). </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Specifically, the attached press
release discusses non-GAAP net loss and non-GAAP profitability, which are non-GAAP
financial measures, and reconciles the Company&#146;s historic non-GAAP net loss to its
historic net loss as determined in accordance with GAAP. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34.0 million in each of 2005 and 2006 and restructuring charges of between
$80 million and $85 million in 2005 and between $35 million and $45 million in 2006, the
Company is unable to provide a quantitative reconciliation because the items that would be
excluded are difficult to predict and estimate and are primarily dependent on future
events. </FONT></P>

<!-- MARKER FORMAT-SHEET="Para Flush" FSL="Default" -->
<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>The Company&#146;s management uses
these non-GAAP financial measures to gain a better understanding of the Company&#146;s
core operating results and future prospects, consistent with how management measures and
forecasts the Company&#146;s performance, especially when comparing such results to
previous periods or forecasts or to those of the Company&#146;s competitors. These
measures are also used by the Company&#146;s management in their financial and operating
decision-making and for compensation purposes.</FONT></P>

<P><FONT FACE="Times New Roman, Times, Serif" SIZE=2>These non-GAAP measures exclude certain
non-operational and restructuring charges, non-cash charges and specified other charges
that are included in the most directly comparable GAAP measures. The Company excludes
these items because it believes they are outside of the Company&#146;s normal operations
and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude:</FONT></P>

<p align=center><font face="Times New Roman, Times, Serif" size=2>2</font></p>
<hr size=3 noshade>

<table width=100% border=0 cellpadding=0 cellspacing=0>

<tr>
<td align=right valign=top width=5%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=top width=93%><font face="Times New Roman, Times, Serif" size=2>Costs associated with the Company&#146;s 2005 strategic refinement and restructuring, such as reducing
overhead and consolidating facilities, resulting from the restructured relationship
between Schering-Plough and the Company for INTEGRILIN&reg; (eptifibatide) Injection and
the reduction in the Company&#146;s inflammation discovery programs. The Company believes
that the costs related to these restructuring activities are not indicative of the
Company&#146;s normal operating costs.</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Costs associated with the Company&#146;s 2003 restructuring effort, such as reducing
overhead and consolidating facilities. The Company believes that the costs related to
these restructuring activities are not indicative of the Company&#146;s normal operating
costs.</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 11 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
Company&#146;s newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies.</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top width=5%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top width=1%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom width=93%><font face="Times New Roman, Times, Serif" size=2>Costs associated with the Company&#146;s debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the put
premiums the Company has placed on its convertible notes because the Company considers
these costs to be nonoperational and nonrecurring and therefore not necessarily indicative
of the Company&#146;s future financial commitments.</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>
<tr>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&#149;</font></td>
<td align=right valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td align=left valign=bottom><font face="Times New Roman, Times, Serif" size=2>Expense associated with stock based compensation because the Company believes that
available valuation methodologies and assumptions related to employee stock options may
result in estimates of option values that are misleading in the comparison of the
Company&#146;s financial results to previous periods or to those of the Company&#146;s
competitors and do not provide meaningful insight into the Company&#146;s ongoing
operations.</font></td>
</tr>
</table>













<p align=center><font face="Times New Roman, Times, Serif" size=2>3</font></p>
<hr size=3 noshade>




<p align=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b><a name="sig">SIGNATURE</a></b></font></p>

<p><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.</font></p>




<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td colspan=2><font face="Times New Roman, Times, Serif" size=2>MILLENNIUM PHARMACEUTICALS, INC.<br>(Registrant)<br><br></font></td>
</tr>
<tr valign=bottom>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>Date: October 26, 2005&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>By&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>/s/&nbsp;&nbsp;MARSHA H. FANUCCI</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2></font><hr noshade></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Marsha H. Fanucci</font></td>
</tr>
<tr valign=top>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=30%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=4%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=36% align=left><font face="Times New Roman, Times, Serif" size=2>Senior Vice President and Chief Financial Officer</font></td>
</tr>
</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>

<p><font face="Times New Roman, Times, Serif" size=2><b><a name="index">EXHIBIT INDEX</a></b></font></p>

<table border=0 cellpadding=0 cellspacing=0>
<tr valign=bottom>
<th width=9% align=center colspan=2><font face="Times New Roman, Times, Serif" size=2>Exhibit No.<br></font><hr noshade></th>
<th width=3%>&nbsp;</th>
<th width=68% align=center><font face="Times New Roman, Times, Serif" size=2>Description<br></font><hr noshade></th>
<th width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></th>
</tr>
<tr valign=top>
<td width=3%><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
<td width=6%><font face="Times New Roman, Times, Serif" size=2>99.1</font></td>
<td width=3%>&nbsp;</td>
<td width=68% align=left><font face="Times New Roman, Times, Serif" size=2>Press Release of Millennium Pharmaceuticals, Inc.
dated October 26, 2005
</font></td>
<td width=20% align=left><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
</tr>

</table>




<p align=center><font face="Times New Roman, Times, Serif" size=2>4</font></p>
<hr noshade size=3>











</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "fm8k10262005.htm", "description": "FORM 8-K", "secsgml_size_bytes": 21058}]
{"company-data": {"conformed-name": "MILLENNIUM PHARMACEUTICALS INC", "cik": "0001002637", "assigned-sic": "2834", "irs-number": "043177038", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-28494", "film-number": "051157391"}, "business-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139", "phone": "6176797000"}, "mail-address": {"street1": "40 LANDSDOWNE STREET", "city": "CAMBRIDGE", "state": "MA", "zip": "02139"}}
Form 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report  (Date of earliest event reported):    October 20, 2005
MILLENNIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware
0-28494
04-3177038
(State or other jurisdiction
of incorporation)
(Commission file number)
(IRS Employer
Identification No.)
40 Landsdowne Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (zip code)
(617)  679-7000
(Registrant's telephone number, including area code)
Not applicable
(Former name or former address if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Item   1.01
Entry into a Material Definitive Agreement.
On October 20, 2005, the Company and
Linda Pine, senior vice president, human resources, agreed that Ms. Pine would be
transitioning to a senior advisory role as a non-executive part-time employee. This change
is expected to take place in the first quarter of 2006 and last through January 2007, at
which point Ms. Pine plans to retire. Ms. Pine will continue to be paid her full time
salary through her retirement date and will also be eligible for a bonus payout under the
Company's 2005 Success Sharing Bonus Plan. In connection with Ms. Pine's change
in employment capacity, she and the Company have agreed that as of January 1, 2006, she
will no longer be eligible for new stock option grants from the Company or for
participation in the Company's 2006 Success Sharing Bonus Plan. Ms. Pine will
continue to vest into her existing stock options through her retirement date and upon her
retirement, Ms. Pine's vested options will remain exercisable as provided in the
plans under which they were issued.
Item   2.02
Results of Operations and Financial Condition.
On October 26, 2005, Millennium
Pharmaceuticals, Inc. (the "Company") issued a press release to report the
Company's financial results for the quarter ended September 30, 2005. The full text
of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.
The information in Item 2.02 and
Exhibit 99.1 of this Form 8-K shall not be deemed "filed" for purposes of
Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
The attached press release contains
non-GAAP financial measures. These non-GAAP measures should be considered in addition to,
not as a substitute for, or superior to other measures of the Company's financial
position prepared in accordance with generally accepted accounting principles (GAAP).
Specifically, the attached press
release discusses non-GAAP net loss and non-GAAP profitability, which are non-GAAP
financial measures, and reconciles the Company's historic non-GAAP net loss to its
historic net loss as determined in accordance with GAAP. With respect to forward-looking
information presented on a non-GAAP basis, other than amortization expenses of
approximately $34.0 million in each of 2005 and 2006 and restructuring charges of between
$80 million and $85 million in 2005 and between $35 million and $45 million in 2006, the
Company is unable to provide a quantitative reconciliation because the items that would be
excluded are difficult to predict and estimate and are primarily dependent on future
events.
The Company's management uses
these non-GAAP financial measures to gain a better understanding of the Company's
core operating results and future prospects, consistent with how management measures and
forecasts the Company's performance, especially when comparing such results to
previous periods or forecasts or to those of the Company's competitors. These
measures are also used by the Company's management in their financial and operating
decision-making and for compensation purposes.
These non-GAAP measures exclude certain
non-operational and restructuring charges, non-cash charges and specified other charges
that are included in the most directly comparable GAAP measures. The Company excludes
these items because it believes they are outside of the Company's normal operations
and, in certain cases, are difficult to forecast accurately for future periods.
Specifically, on both a historic and a forward-looking basis, these non-GAAP measures
exclude:
2
•
Costs associated with the Company's 2005 strategic refinement and restructuring, such as reducing
overhead and consolidating facilities, resulting from the restructured relationship
between Schering-Plough and the Company for INTEGRILIN® (eptifibatide) Injection and
the reduction in the Company's inflammation discovery programs. The Company believes
that the costs related to these restructuring activities are not indicative of the
Company's normal operating costs.
•
Costs associated with the Company's 2003 restructuring effort, such as reducing
overhead and consolidating facilities. The Company believes that the costs related to
these restructuring activities are not indicative of the Company's normal operating
costs.
•
Expense associated with the amortization of acquisition-related intangible assets because
a significant portion of the purchase price for acquisitions may be allocated to
intangible assets that have lives of two to 11 years. Exclusion of the amortization
expense allows comparisons of operating results that are consistent over time for both the
Company's newly acquired and long-held businesses and with both acquisitive and
non-acquisitive peer companies.
•
Costs associated with the Company's debt financing activities such as amortization on
capitalized professional and banking fees and charges related to the fair value of the put
premiums the Company has placed on its convertible notes because the Company considers
these costs to be nonoperational and nonrecurring and therefore not necessarily indicative
of the Company's future financial commitments.
•
Expense associated with stock based compensation because the Company believes that
available valuation methodologies and assumptions related to employee stock options may
result in estimates of option values that are misleading in the comparison of the
Company's financial results to previous periods or to those of the Company's
competitors and do not provide meaningful insight into the Company's ongoing
operations.
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
MILLENNIUM PHARMACEUTICALS, INC.
(Registrant)
Date: October 26, 2005
By
/s/  MARSHA H. FANUCCI
Marsha H. Fanucci
Senior Vice President and Chief Financial Officer
4
EXHIBIT INDEX
Exhibit No.
Description
99.1
Press Release of Millennium Pharmaceuticals, Inc.
dated October 26, 2005
4